文献速递心外重症与机械循环支持

临时体外生命支持:单中心新概念经验

Temporary extracorporeal life support: single-centre experience with a new concept.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2024-01-01

该单中心回顾性分析报告了67例心源性休克患者接受新型单动脉入路ECMELLA 2.0(股静脉,n=56)或2.1(颈静脉,n=11)的结局:39例(58%)在中位支持4天后撤除体外膜氧合,18例(27%)心肌恢复,16例(24%)过渡至持久左心室辅助装置,33例(49%)在支持期间死亡,腋窝入路部位出血9例(13.5%)。作者认为ECMELLA 2.0/2.1是严重心源性休克的可行且有效治疗,单动脉置管技术与相对较低的入路相关并发症发生率相关。

要点

  • 67例心源性休克患者接受ECMELLA 2.0(n=56)或2.1(n=11),中位ECMELLA支持4天后39例(58%)撤除VA-ECMO。
  • 18例(27%)实现心肌恢复,16例(24%)过渡至持久左心室辅助装置,33例(49%)在支持期间死亡。
  • 腋窝入路部位出血9例(13.5%),需手术修复的上肢缺血3例(4.5%),腋窝部位感染6例(9%),围术期卒中10例(15%;6例出血性,4例血栓栓塞性)。

核心结论

  • ECMELLA 2.0/2.1是严重心源性休克的可行且有效治疗,单动脉置管技术与相对较低的入路相关并发症发生率相关。

研究设计与样本

  • 单中心回顾性分析,纳入2020年12月至2022年12月接受ECMELLA 2.0(n=56)和2.1(n=11)的67例连续心源性休克患者。

主要发现

  • 平均年龄60.7±11岁,56例(84%)为男性;心源性休克病因为急性失代偿性慢性心力衰竭35例(52%)、心肌梗死13例(19.5%)、心脏术后综合征16例(24%)、心肌炎3例(4.5%)。
  • 术前31例(46%)接受复苏,53例(79%)使用呼吸机,60例(90%)使用正性肌力药物支持;中位血管活性正性肌力评分32,平均动脉血乳酸8.1 mmol/l。
  • 39例(58%)在中位ECMELLA支持4天后撤除静脉-动脉体外膜氧合;18例(27%)实现心肌恢复,16例(24%)过渡至持久左心室辅助装置。
  • 33例(49%)在支持期间死亡(25例在ECMELLA上,8例在降阶梯后Impella上),其中9例(13%)接受姑息治疗。
  • 腋窝入路部位出血9例(13.5%),需手术修复的上肢缺血3例(4.5%),腋窝部位感染6例(9%),围术期卒中10例(15%;6例出血性,4例血栓栓塞性)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The combination of veno-arterial extracorporeal membrane oxygenation with a micro-axial flow pump (ECMELLA) is increasingly used for cardiogenic shock (CS) therapy. We report our experience with a novel single-artery access ECMELLA setup with either femoral (2.0) or jugular venous cannulation (2.1), respectively. METHODS: Data from 67 consecutive CS patients treated with ECMELLA 2.0 (n = 56) and 2.1 (n = 11) from December 2020 and December 2022 in a tertiary cardiac center were retrospectively analyzed. RESULTS: The mean age was 60.7 ± 11 years, 56 patients (84%) were male. CS aetiology was acute on chronic heart failure (n = 35, 52%), myocardial infarction (n = 13, 19.5%), postcardiotomy syndrome (n = 16, 24%) and myocarditis (n = 3, 4.5%). Preoperatively 31 patients (46%) were resuscitated, 53 (79%) were on a ventilator and 60 (90%) were on inotropic support. The median vasoactive inotropic score was 32, and the mean arterial lactate was 8.1 mmol/l. In 39 patients (58%), veno-arterial extracorporeal membrane oxygenation was explanted after a median ECMELLA support of 4 days. Myocardial recovery was achieved in 18 patients (27%), transition to a durable left ventricular assist device in 16 (24%). Thirty-three patients (n = 33; 49%) died on support (25 on ECMELLA and 8 on Impella after de-escalation), 9 (13%) of whom were palliated. Axillary access site bleeding occurred in 9 patients (13.5%), upper limb ischaemia requiring surgical revision in 3 (4.5%). Axillary site infection occurred in 6 cases (9%), and perioperative stroke in 10 (15%; 6 hemorrhagic, 4 thromboembolic). CONCLUSIONS: ECMELLA 2.0/2.1 is a feasible and effective therapy for severe CS. The single-artery cannulation technique is associated with a relatively low rate of access-related complications.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Nersesian G, Lewin D, Ott S, et al. Temporary extracorporeal life support: single-centre experience with a new concept. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 38490254. doi:10.1093/icvts/ivae043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。